Epidemiology of Bacteremia at Two Tertiary ICUs in Switzerland

NCT05236283 — Completed, 395 participants, Insel Gruppe AG, University Hospital Bern

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Duration of Antimicrobial Treatment for Bloodstream Infections in Swiss Critically Ill Patients - Retrospective Double Center Study

Registry	NCT05236283
Status	Completed
Study type	Observational
Enrollment	395 (Actual)
Sponsor	Insel Gruppe AG, University Hospital Bern (Other)
Conditions	Bacteremia
Interventions	Blood Culture (Diagnostic test)
Dates	start 2022-02-01, primary completion 2022-03-01, completion 2022-03-30, first posted 2022-02-11, last updated 2023-01-26
Locations	1 site in Switzerland

-Summary

The objectives of the retrospective cohort study is to describe the actual current practice of antibiotic treatment duration for bloodstream infections in critically ill patients at two tertiary hospitals (ICU Inselspital Bern and ICU CHUV Lausanne), to examine patient, pathogen and infectious syndrome factors associated with selection of shortened treatment duration, and to describe the expected time course of clinical resolution among bacteremic patients.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
Bern ICU		Diagnostic Test: Blood Culture
Lausanne ICU		Diagnostic Test: Blood Culture

Blood Culture (Diagnostic test): Blood Culture

+Outcome measures

Primary outcomes

Antibiotic Treatment Duration [Hospital discharge, expected to be on average ca. 15-20 days]: Days of adequate antibiotic treatment in Patients with Bacteremia

Secondary outcomes

Days of ICU stay [ICU discharge, expected to be on average ca. 5-15 days]: Days of ICU Stay in Patients with Bacteremia
Days of hospital stay [Hospital discharge, expected to be on average ca. 15-25 days]: Days of Inhospital Stay in Patients with Bacteremia

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

Patient has a positive blood culture with a pathogenic organism Patient is critically ill at the time the blood culture was collected as defined by the following:

1. was treated at the ICU/IMC at the time of blood culture collection;
2. or has been admitted to ICU/IMC in the 48 hours after blood culture collection

Exclusion Criteria:

1. Patient has a single positive blood culture with a common contaminant organism:

   * coagulase negative staphylococci;
   * Bacillus spp.;
   * Corynebacterium spp.;
   * Propionibacterium spp.;
   * Aerococcus spp.;
   * Micrococcus spp.
2. Explicit documentation that the patient does not want to participate in any study

+Locations (1)

Facility	City	Country	Status
Departement of Intensive Care Medicine	Bern	Switzerland

+Publications

Results publication: Zuercher P, Moser A, Frey MC, Pagani JL, Buetti N, Eggimann P, Daneman N, Fowler R, Que YA, Prazak J. The effect of duration of antimicrobial treatment for bacteremia in critically ill patients on in-hospital mortality - Retrospective double center analysis. J Crit Care. 2023 Apr;74:154257. doi: 10.1016/j.jcrc.2023.154257. Epub 2023 Jan 23. PMID 36696827

+Investigators

Josef Prazak, MD, PhD, Principal investigator, Insel Gruppe AG, University Hospital Bern